Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.17
+0.19 (1.73%)
At close: Nov 21, 2025, 4:00 PM EST
11.13
-0.04 (-0.36%)
Pre-market: Nov 24, 2025, 7:00 AM EST
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$541,818
Profits / Employee
-$1,129,604
Market Cap
971.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 192 | 50 | 35.21% |
| Dec 31, 2023 | 142 | 9 | 6.77% |
| Dec 31, 2022 | 133 | 12 | 9.92% |
| Dec 31, 2021 | 121 | 32 | 35.96% |
| Dec 31, 2020 | 89 | 29 | 48.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KURA News
- 4 days ago - Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript - Seeking Alpha
- 10 days ago - Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia - GlobeNewsWire
- 10 days ago - US FDA approves Kura Oncology's blood cancer therapy - Reuters
- 11 days ago - Kura Oncology to Participate in Upcoming Investor Conference - GlobeNewsWire
- 16 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Kura Oncology Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 20 days ago - Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin - GlobeNewsWire